Sera Labs offers 1,500 recombinant proteins

Published: 1-Jun-2010
Research & Development

Including cytokines, growth factors, chemokines, hormones, enzymes and viral antigens

Sera Laboratories International, a UK-based serum specialist, has developed more than 1,500 recombinant proteins for a variety of species including human, mouse, rat, porcine, bovine and chicken. The collection includes cytokines, growth factors, chemokines, hormones, enzymes and viral antigens.

Sera Lab’s recombinant proteins are mainly derived from bacterial systems and also include mammalian, yeast, insect and plant sources. All are rigorously tested to ensure excellent quality and biological activity.

With headquarters and storage in Haywards Heath, West Sussex and a cell culture research facility in France, Sera Lab offers a complete range of animal-based research products from a variety of origins. The company supplies laboratories in more than 30 countries worldwide, either directly or through distributors.

See more

You may also like

Manufacturing

Exploring Ireland’s thriving life sciences sector

Read more
NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing

Trending Articles

  1. Bath scientists design peptide "switch" that keeps Parkinson’s protein in its healthy form Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to Parkinson’s disease and related dementias
  2. Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
  3. Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
  4. Designing and developing bioconjugates for clinical success Abzena shares new insights and technologies to accelerate safe and effective ADC development
  5. Kindeva to showcase complex drug delivery expertise at CPHI 2025 Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Exploring Ireland’s thriving life sciences sector

NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing
Manufacturing

Intertronics releases white paper on process validation for medical device bonding

The new guidance helps manufacturers cut costs, save time and ensure ISO and FDA compliance by designing out variability and improving process reliability from the start
Regulatory

FDA lifts clinical hold on Neurizon’s NUZ-001 for ALS trial entry

The decision clears the path for NUZ-001 to join the HEALEY ALS Platform Trial later this year, advancing Neurizon’s lead therapy for amyotrophic lateral sclerosis and strengthening its regulatory and development pipeline
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part II)

Part II of this article focuses on defining what “good” looks like in biorepository infrastructure, validation and documentation, providing practical guidance to create resilient, compliant storage solutions that underpin successful oncology research
Research & Development

Daiichi Sankyo launches third global research institute in San Diego

The company expands its international research footprint with a new San Diego institute, strengthening collaborations in one of the world’s leading life-science hubs and advancing its global drug discovery strategy
Research & Development

Bath scientists design peptide "switch" that keeps Parkinson’s protein in its healthy form

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to Parkinson’s disease and related dementias
Manufacturing

Designing and developing bioconjugates for clinical success

Abzena shares new insights and technologies to accelerate safe and effective ADC development
Subscribe now